Olema Pharmaceuticals (NASDAQ: OLMA) — Perfil da empresa, notícias e dados financeiros
Olema Pharmaceuticals focuses on targeted therapies for women's cancers, advancing OP-1250 for breast and hormone-driven cancers.
Olema Pharmaceuticals
Olema Pharmaceuticals (NASDAQ:OLMA) is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. With a deep commitment to addressing unmet medical needs, their primary project revolves around advancing their lead candidate, OP-1250, a novel therapy in clinical trials aiming at both the treatment of breast cancer and other hormone-driven cancers. Through groundbreaking research and a dedicated team, Olema is striving to bring innovative solutions from the laboratory to patients, aiming to improve outcomes and quality of life for those facing these challenging diagnoses. Their objective is not only to pioneer advancements in the oncology field but also to establish a legacy of contributing significant breakthroughs in cancer care.
Resumo
Operações
Produtos e/ou serviços de Olema Pharmaceuticals
- OP-1250, a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) for metastatic breast cancer treatment.
- Investigation of OP-1250 in combination therapies for broader efficacy in cancer treatment, exploring synergies with established cancer therapies.
- Development of next-generation SERDs aimed at overcoming resistance to current therapies and providing new options for hormone receptor-positive breast cancer.
- Expansion into targeted therapies for other hormonally driven cancers, leveraging the technology platform behind OP-1250.
- Preclinical studies on novel oncology targets, identifying promising compounds for future pipeline expansion.
- Collaborations with academic and industry partners to accelerate the development of its oncology portfolio and share expertise.
equipe executiva do Olema Pharmaceuticals
- Sean P. BohenPresident, CEO & Director
- Shawnte M. MitchellChief Legal Officer & Corporate Secretary
- Jason O'ByrneCFO, Principal Financial Officer & Accounting Officer
- David C. MylesChief Scientific Officer
- Courtney O'KonekVice President of Corporate Communications
- Julie DexterSenior VP & Head of People
- Naseem ZojwallaChief Medical Officer
- Richard HernandezSenior Vice President of Clinical Development Operations
- Mark ShilkrutSenior Vice President of Clinical Development
- Kamesh KuchimanchiSenior Vice President of Regulatory Affairs & Quality Assurance
Últimas notícias sobre a Olema Pharmaceuticals
Principais indicadores financeiros
Resultados divulgados pela Olema Pharmaceuticals, em USD.
- Cap. de mercado
- 616 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -2.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -178,7 mi | -162,5 mi | |
| 0 | -142,3 mi | -129,5 mi | |
| 0 | -105 mi | -96,7 mi | |
| 0 | -107 mi | -102,6 mi |